Internal Medicine · 2017 · 24 citations · 8 references
PharmacyOncologyToxicologyCancer GeneticsChemotherapyDna RepairAdverse Effects Of ChemotherapyCytotoxic ChemotherapyDna DamageDna Repair DefectsMalignant NeoplasmsToxicity ManagementAdverse Drug EventsDna Cross-linkingDna Repair MechanismsDna Repair PathwaysImpaired Dna RepairPlatinum-based AgentsPlatinum-induced Dna CrosslinksSerious Adverse Events
Xeroderma pigmentosum (XP) is a genetic disease in which DNA repair mechanisms are impaired. Cisplatin (CDDP) exerts cytotoxic effects by forming mainly intrastrand DNA cross-links, and sensitivity to CDDP depends on the DNA repair system. Several in vitro studies have suggested that treatment with CDDP may cause enhanced adverse events as well as anti-tumor activity in cancer patients with XP. This article is the first to describe two cancer patients with XP showing severe adverse events following CDDP-based chemotherapy. Physicians should pay attention when administering CDDP in cancer patients with XP.
8
Thierry Le Chevalier, D. Brisgand, Jean‐Yves Douillard et al. · Journal of Clinical Oncology · 1994 · 824 citations
Medicine, Oncology, Pharmacology +12
Agnieszka Woźniak, John J. Crowley, S P Balcerzak et al. · Journal of Clinical Oncology · 1998 · 567 citations
Medicine, Oncology, Pharmacology +11
A Role for Polymerase η in the Cellular Tolerance to Cisplatin-Induced Damage
Mark R. Albertella, Catherine Green, Alan R. Lehmann et al. · Cancer Research · 2005 · 204 citations
Bypass of DNA Lesions Generated During Anticancer Treatment with Cisplatin by DNA Polymerase η
Aaron Alt, Katja Lammens, Claudia Chiocchini et al. · Science · 2007 · 199 citations